C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

As described in a recent JAMA Viewpoint, the proposed national HCV elimination program intends to engage underserved populations in need of HCV treatment by working closely with grassroots ...

Atea Pharmaceuticals, Inc. ( (AVIR)) has released its Q3 earnings. Here is a breakdown of the information Atea Pharmaceuticals, Inc. presented to its investors. Atea Pharmaceuticals, Inc. is a ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

Please provide your email address to receive an email when new articles are posted on . Among 133,732 veterans with HCV, 80.1% initiated treatment and 91.6% achieved SVR. Younger veterans were less ...

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...

Please provide your email address to receive an email when new articles are posted on . Georgia’s hepatitis C virus elimination program made significant progress in helping diagnose patients and begin ...

Pills can cure infection with the hepatitis C virus (HCV), but getting the medication to patients who need treatment can be a challenge. Many patients with HCV use drugs such as methamphetamine or ...

Dr. James W. Galbraith joined the University of Alabama at Birmingham (UAB) Emergency Medicine faculty in 2008. In 2011, Dr. Galbraith led the implementation of emergency department (ED) non-targeted, ...